Antibodies to cytotoxic t-lymphocyte associated protein 4 that potentiate t cell activation
Antibodies targeting CTLA-4 as agonists activate T cells, addressing the limitations of current inhibitors by enhancing T cell activation and reducing adverse events, offering a targeted cancer treatment approach.
WO2026136502A1PCT designated stage Publication Date: 2026-06-25GEORGIAMUNE INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- GEORGIAMUNE INC
- Filing Date
- 2025-12-17
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
Current CTLA-4 inhibitors, such as ipilimumab, cause significant immune-related adverse events due to nonspecific activation of the immune system, and there is a need for agents that can activate T cells instead of inhibiting them.
Method used
Development of antibodies or antigen-binding fragments with specific binding affinity to CTLA-4 that act as agonists, enhancing T cell activation and potentially increasing interferon-gamma production without blocking CTLA-4's interaction with CD80 or CD86.
Benefits of technology
The antibodies effectively activate T cells, enhancing interferon-gamma production and providing a targeted approach to cancer treatment with reduced adverse events.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000019_0001 
Figure IMGF000020_0001 
Figure IMGF000021_0001
Abstract
This disclosure relates to antibodies and antigen-binding fragments thereof that immunospecifically bind to CTLA-4 and are agonists that activate T cells and / or potentiate T cell activation. This disclosure relates to methods for the treatment of cancer comprising administration of the anti-CTLA-4 antibodies or antigen-binding fragments to a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art